Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 1.00 |
| ▸ | INSR | P06213 | 5/20 | 0.84 |
| ▸ | IGF1R | P08069 | 5/20 | 0.84 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.84 |
| ▸ | MET | P08581 | 2/20 | 0.79 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.78 |
| ▸ | PLK4 | O00444 | 1/20 | 0.78 |
| ▸ | STK25 | O00506 | 1/20 | 0.78 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.78 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.78 |
| ▸ | CASK | O14936 | 1/20 | 0.78 |
| ▸ | AURKA | O14965 | 1/20 | 0.78 |
| ▸ | GAK | O14976 | 1/20 | 0.78 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.78 |
| ▸ | MUSK | O15146 | 1/20 | 0.78 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.78 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.78 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.78 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.78 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21847017 | 0.97 | EGFR (1.00) | EGFRINSRIGF1RALKLRRK2 | |
| SCHEMBL21846977 | 0.94 | EGFR (1.00) | EGFRINSRIGF1RALKLRRK2 | |
| SCHEMBL22087949 | 0.93 | EGFR (1.00) | EGFRINSRIGF1RALKMET | |
| SCHEMBL26906684 | 0.93 | EGFR (0.87) | EGFRINSRIGF1RALKMET | |
| SCHEMBL29609251 | 0.93 | EGFR (1.00) | EGFRINSRIGF1RALKROS1 | |
| SCHEMBL21847015 | 0.93 | EGFR (1.00) | EGFRINSRIGF1RALKROS1 | |
| SCHEMBL26906894 | 0.93 | EGFR (0.86) | EGFRINSRIGF1RALKMET | |
| SCHEMBL21847004 | 0.92 | EGFR (1.00) | EGFRLRRK2 | |
| SCHEMBL21847005 | 0.92 | EGFR (0.87) | EGFRINSRIGF1RALKZAP70 | |
| SCHEMBL30936860 | 0.92 | EGFR (1.00) | EGFRLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3640246-B1 | N2,N4-DIPHENYLPYRIMIDINE-2,4-DIAMINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | KOREA RES INST CHEMICAL TECH (KR) | 2023-11-01 | — | — | EP | claimed |
| WO-2023201024-A1 | COMPOSITION AND TREATMENT FOR CANCER WITH MUTATIONS | Bridge Biotherapeutics, Inc. (KR) | 2023-10-19 | — | — | WO | claimed |
| US-20230330112-A1 | COMPOSITION AND TREATMENT FOR CANCER WITH MUTATIONS | Bridge Biotherapeutics, Inc. (KR) | 2023-10-19 | — | — | US | claimed |
| US-20220249482-A1 | N2,N4-DIPHENYLPYRIMIDINE-2,4-DIAMINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-08-11 | — | — | US | claimed |
| US-11253516-B2 | N2,N4-diphenylpyrimidine-2,4-diamine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-02-22 | — | — | US | claimed |
| US-20200179384-A1 | N2,N4-DIPHENYLPYRIMIDINE-2,4-DIAMINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2020-06-11 | — | — | US | claimed |
| EP-3640246-A1 | N2,N4-DIPHENYLPYRIMIDINE-2,4-DIAMINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | Korea Research Institute of Chemical Technology (KR) | 2020-04-22 | — | — | EP | claimed |
| CN-110740999-A | N2, N4-diphenylpyrimidine-2, 4-diamine derivative, process for producing the same, and pharmaceutical composition for preventing or treating cancer comprising the same as active ingredient | 韩国化学研究院 | 2020-01-31 | — | — | CN | claimed |
| EP-4313969-A1 | N2-PHENYLPYRIMIDINE-2,4-DIAMINE COMPOUNDS, AND PREPARATION METHODS AND METHODS OF USE THEREOF | Bridge Biotherapeutics, Inc. (KR) | 2024-02-07 | — | — | EP | disclosed |
| CN-117203199-A | N2-phenylpyrimidine-2, 4-diamine compounds, methods of making and using the same | 毕利吉生物科技股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| EP-3640246-B1 | N2,N4-DIPHENYLPYRIMIDINE-2,4-DIAMINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | KOREA RES INST CHEMICAL TECH (KR) | 2023-11-01 | — | — | EP | disclosed |
| WO-2023201024-A1 | COMPOSITION AND TREATMENT FOR CANCER WITH MUTATIONS | Bridge Biotherapeutics, Inc. (KR) | 2023-10-19 | — | — | WO | disclosed |
| US-20230330112-A1 | COMPOSITION AND TREATMENT FOR CANCER WITH MUTATIONS | Bridge Biotherapeutics, Inc. (KR) | 2023-10-19 | — | — | US | disclosed |
| US-20230330112-A1 | COMPOSITION AND TREATMENT FOR CANCER WITH MUTATIONS | Bridge Biotherapeutics, Inc. (KR) | 2023-10-19 | — | — | US | disclosed |
| US-11253516-B2 | N2,N4-diphenylpyrimidine-2,4-diamine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-02-22 | — | — | US | disclosed |
| US-11253516-B2 | N2,N4-diphenylpyrimidine-2,4-diamine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-02-22 | — | — | US | disclosed |
| US-20200179384-A1 | N2,N4-DIPHENYLPYRIMIDINE-2,4-DIAMINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2020-06-11 | — | — | US | disclosed |
| US-20200179384-A1 | N2,N4-DIPHENYLPYRIMIDINE-2,4-DIAMINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2020-06-11 | — | — | US | disclosed |
| EP-3640246-A1 | N2,N4-DIPHENYLPYRIMIDINE-2,4-DIAMINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | Korea Research Institute of Chemical Technology (KR) | 2020-04-22 | — | — | EP | disclosed |
| CN-110740999-A | N2, N4-diphenylpyrimidine-2, 4-diamine derivative, process for producing the same, and pharmaceutical composition for preventing or treating cancer comprising the same as active ingredient | 韩国化学研究院 | 2020-01-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200179384-A1 | N2,N4-DIPHENYLPYRIMIDINE-2,4-DIAMINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | FLT3, EGFR, ERBB2 | EGFR 2/4885INSR 2643/4885IGF1R 541/4885 |
| US-20220249482-A1 | N2,N4-DIPHENYLPYRIMIDINE-2,4-DIAMINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | FLT3, EGFR, ERBB2 | EGFR 2/4885INSR 2643/4885IGF1R 541/4885 |
| US-20230330112-A1 | COMPOSITION AND TREATMENT FOR CANCER WITH MUTATIONS | EGFR, ERBB2, ERBB3 | EGFR 1/4885INSR 629/4885IGF1R 64/4885 |
| US-11253516-B2 | N2,N4-diphenylpyrimidine-2,4-diamine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer | FLT3, EGFR, ERBB2 | EGFR 2/4885INSR 2643/4885IGF1R 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.